Cipro Articles
India Claws Back "Unintended"Profits
12 June 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
UK Code Authority May Become Self-Supporting
20 March 1995
Barr Go-Ahead For Generic Ciprofloxacin?
16 January 1995
Polarization Concerns For Chemical/Drug Majors?
16 January 1995
Ciprofloxacin and Traveller's Diarrhea
12 December 1994
Bayer A "Moderate Outperformer"
12 December 1994
Bayer Adapting Pharma Business
12 December 1994
Bayer's Profits Rise As Group Refocuses
5 December 1994
Abbott Unveils New DNA Gyrase Inhibitors
7 November 1994
New Quinolone: Daiichi's DU-6859a
7 November 1994
USA's Top-Selling Drugs In 1993
24 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
French Reforms Hit Antibiotic Sales
3 October 1994
Zeneca Gets First Full Approval For Merrem
5 September 1994
Forest Close To Filing For Monurol In USA?
8 August 1994
ANTIBIOTICS IN SEPSIS INITIATION
27 June 1994
ALCON LAUNCH IN UK
11 April 1994
TRAVELLER'S DIARRHEA AND CIPROFLOXACIN
4 April 1994
BAYER'S OPTIMISTIC FORECAST FOR 1994
28 March 1994
COST-CUTTING IN SPANISH HEALTH CARE
7 March 1994
SPI INTRODUCES ANTIBIOTIC
17 January 1994
FLUOROQUINOLONES - SEIZURE RATES
11 October 1993
EXPANDED INDICATION FOR CIPROXIN
20 September 1993
US RESEARCH INTO CYSTIC FIBROSIS
12 July 1993
INDIA: A PATENT REGIME FOR DRUG SECURITY
21 June 1993
BAYER'S GLUCOBAY LAUNCHED IN UK
14 June 1993
SPANISH FIRM ESTEVE INTERNATIONALIZES
10 May 1993
GERMAN PATENT COVER "THREAT"
19 April 1993
NEW LOMEFLOXACIN EFFICACY DATA
19 April 1993
BAYER ITALY HIT BY EXCHANGE RATES
5 April 1993
QUINOLONE SAFETY NOTED BY CSM
15 March 1993
ICI AT "BREAKING POINT" WITH DEMERGER
14 December 1992
ICI AND MILES TO COPROMOTE CIPRO
5 October 1992
Study on ciprofloxacin interactions
29 June 1992
STOCK MARKET COMMENTARY: EUROPE
4 May 1992
BAYER'S CIPROXIN & UTIs
27 April 1992
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
"ROLLING" NDA FOR ADRIA'S RIFABUTIN
13 April 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
